TGFB1 and colorectal carcinoma: Moreover, these mice were resistant to immune checkpoint therapylike human patients with pMMR/MSS CRC are in the clinic.5,33 However, we showed that TGFβ inhibition mediated by galunisertib(at high concentrations) combined with immune checkpoint therapy couldovercome such resistance and synergize with immunotherapies to cureestablished metastases.5 For these experiments,we used the 1× galunisertib dosage (800 mg/kg BID).5